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Sir,
We appreciate the constructive comments of Dr Vassiliou and
Dr Andreopoulos to our publication ‘Tumour response interpreta-
tion with new tumour response criteria vs the World Health
Organisation criteria in patients with bone-only metastatic breast
cancer’ (Hamaoka et al, 2010). We agree that the MDA criteria
might become more accurate if they encompassed a greater scope
of quantitative measurements. However, we intentionally avoided
discussing developing criteria based exclusively on quantitative
measurements because the quantitative measurements of radio-
graphic changes in bone have historically proven to be extremely
difficult, would therefore obligate us to exclude a large number
of bone metastases as ‘unmeasurable’ and thus limit the use of
our criteria.
We have conducted a prospective clinical trial of bone tumour
imaging comparing the MDA criteria with the International Union
Against Cancer and World Health Organization criteria. The trial
results are now being analysed, and we will soon prepare a report on
our findings. From the preliminary results of the prospective data,
we once again recognise the importance of change in lesion density
(with computed tomography) and/or signal intensity (with magnetic
resonance imaging, MRI) as an indicator of response to therapy.
In addition to measuring the sum of the largest perpendicular
dimensions of measurable bone lesions, another potential way
to incorporate quantitative measurements into the MDA response
criteria would be to include response measurements within
a region of interest of specifically defined size to determine
Houndsfield unit change on CT. However, the precision of
repeated measurements is a major concern regarding the use of
quantitative CT in our response criteria. It has been shown that
many variables such as scanner type (e.g., 4 as compared with
16 channels), pitch, gantry rotation speed, table speed, table
height, and X-ray tube temperature can affect the precision of bone
mineral density measurements, and variability of 1.4–3.6% has
been reported (Bligh et al, 2009). Small differences in precision can
be cumulative and lead to erroneous results when allowed to
accumulate over several time points, unless painstaking quality
control methods are used, such as scanning each patient using
the same type of scanner (preferably the same exact scanner) with
the same imaging parameters. This can be logistically difficult in
a large practice. Similar issues arise regarding the precision of
repeated MRI measurements, and scan parameters must also be
uniform to permit adequate comparison of quantitative MRI
results using standardised MR scan parameters over many time
points on different scans. Another possibility is to measure
changes in the standardised uptake value on fluorodeoxyglucose
positron emission tomography–computed tomography. Regard-
less of the methods of quantification, any changes to the MDA
response criteria would need to be tested in prospective clinical
trials by comparison with the current MDA criteria to determine
whether adding additional quantitative indicators would be truly
useful in defining a clinically relevant response. It is the opinion of
the authors that the qualitative portions of the MDA criteria
constitute their greatest strength by allowing outcome determi-
nation of a wide variety of bone metastases in a simple and
straightforward manner.
REFERENCES
Bligh M, Bidaut L, White RA, Murphy WA, Stevens DM, Cody DD (2009)
Helical multidetector row quantitative computed tomography (QCT)
precision. Acad Radiol 16: 150–159
Hamaoka T, Costelloe CM, Madewell JE, Liu P, Berry DA, Islam R,
Theriault RL, Hortobagyi GN, Ueno NT (2010) Tumour response
interpretation with new tumour response criteria vs the World Health
Organisation criteria in patients with bone-only metastatic breast cancer.
Br J Cancer 102(11): 651–657
Published online 27 July 2010
*Correspondence: Dr NT Ueno; E-mail: nueno@mdanderson.org
British Journal of Cancer (2010) 103, 927
& 2010 Cancer Research UK All rights reserved 0007– 0920/10
www.bjcancer.com